Grant✓ Small businesses may apply
Innovative Screening Approaches and Therapies for Screenable Disorders in Newborns (R01 - Clinical Trial Optional)
National Institutes of Health
- Opportunity #
- PAR-25-265
- Agency
- National Institutes of Health
- ALN (CFDA)
- 93.865
- Status
- posted
- Posted
- Dec 2, 2024
- Closes
- Nov 16, 2027
- Funding instrument
- Grant
- Category
- Health, Income Security and Social Services
- Cost sharing required
- No
Who can apply
- •Native American tribal governments (Federally recognized)
- •For profit organizations other than small businesses
- •Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education
- •Public housing authorities/Indian housing authorities
- •Small businesses
- •Independent school districts
- •Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education
- •County governments
- •Public and State controlled institutions of higher education
- •Others (see text field entitled "Additional Information on Eligibility" for clarification)
- •Native American tribal organizations (other than Federally recognized tribal governments)
- •State governments
- •Special district governments
- •Private institutions of higher education
- •City or township governments
Other Eligible Applicants include the following:
Alaska Native and Native Hawaiian Serving Institutions; Asian American Native American Pacific Islander Serving Institutions (AANAPISISs); Eligible Agencies of the Federal Government; Faith-based or Community-based Organizations; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Indian/Native American Tribal Governments (Other than Federally Recognized); Non-domestic (non-U.S.) Entities (Foreign Organizations); Regional Organizations; Tribally Controlled Colleges and Universities (TCCUs) ; U.S. Territory or Possession.
Synopsis
This FOA encourages research relevant to the development of novel screening approaches and/or therapeutic interventions for potentially fatal or disabling conditions that have been identified through newborn screening, as well as for "high priority" genetic conditions where screening may be possible in the near future.Having an accurate screening test, as well as demonstrating the benefits of early intervention or treatment, are important criteria for including a condition on a newborn screening panel. This FOA defines a "high priority" condition as one where screening is not currently recommended, but infants with the condition would significantly benefit from early identification and treatment.
Contact
National Institutes of Health · grantsinfo@nih.gov